Abbott Laboratories (ABT) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate strong growth prospects in diabetes care and heart failure, with positive developments in new product launches like the dual-analyte sensor and AVEIR pacemaker. Despite headwinds in diagnostics and China's market, the company's strategic focus on innovation and expansion in high-growth segments like Structural Heart and EP suggest a positive outlook. However, the lack of detailed guidance on CMS coverage and tariff impacts introduces some uncertainty, but overall, the sentiment leans towards a positive stock price movement.
Key Financial Performance
Organic Sales Growth 7.5% excluding COVID test sales, driven by double-digit growth in Medical Devices and high single-digit growth in Established Pharmaceuticals.
Earnings Per Share (EPS) $1.30, up high single digits compared to last year and up double digits excluding the impact of the expected large year-over-year decline in COVID test sales.
Nutrition Sales Growth 4%, led by Adult Nutrition business with 10% growth in international markets. Growth driven by strong demand for Ensure and Glucerna, supported by favorable demographic and dietary trends.
Diagnostics Sales Growth Modest growth excluding COVID testing sales. Core Lab Diagnostics grew 7% excluding China, driven by durable demand in markets like the U.S. and growth in Point of Care Diagnostics by 8%.
Established Pharmaceuticals (EPD) Sales Growth 7%, led by double-digit growth in key 15 markets. Growth driven by strong demand in therapeutic areas like gastroenterology, cardiometabolic, and pain management.
Medical Devices Sales Growth 12.5%, driven by double-digit growth in Diabetes Care, Electrophysiology, Cardiac Rhythm Management, Heart Failure, and Structural Heart. Continuous glucose monitors grew 17%.
Adjusted Gross Margin 55.8% of sales, reflecting a decrease compared to the prior year due to the impact of tariffs.
Adjusted Operating Margin 23% of sales, reflecting an increase of 40 basis points compared to the prior year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Glucerna version: Launched a new version of Glucerna with only 1 gram of sugar.
New Ensure version: Launching a new version of Ensure with 42 grams of protein later this month.
Volt PFA catheter: Launched in Europe, receiving positive feedback and driving double-digit growth in ablation catheters.
TriClip: Received regulatory approval in Japan as the first minimally invasive treatment for tricuspid regurgitation.
TAVR valve Navitor: Received CE Mark for expanded indication to treat low or intermediate risk patients for open heart surgery.
AVEIR leadless pacemaker: Strong uptake, expanding market and capturing share in single and dual chamber pacing segments.
Esprit stent: Received CE Mark for below-the-knee resorbable stent for peripheral artery disease.
Eterna spinal cord stimulation device: Strong performance in international markets due to continued uptake and new market launches.
Adult Nutrition: 10% growth in international markets driven by Ensure and Glucerna.
Core Lab Diagnostics: 7% growth outside China, driven by durable demand in markets like the U.S.
EPD (Established Pharmaceuticals): Double-digit growth in key 15 markets, driven by gastroenterology, cardiometabolic, and pain management.
Medical Devices: 12.5% growth driven by Diabetes Care, Electrophysiology, Cardiac Rhythm Management, Heart Failure, and Structural Heart.
Organic sales growth: Achieved 7.5% organic sales growth excluding COVID test sales.
Earnings per share: Increased to $1.30, up high single digits compared to last year.
Adjusted operating margin: Improved to 23% of sales, up 40 basis points from the prior year.
Biosimilar strategy: Advanced regulatory approval for several biosimilars, with planned product and geographic launches on track.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Diagnostics: Challenging market conditions in China are impacting both price and volume, creating a headwind for the Core Lab Diagnostics business.
Foreign Exchange Impact: Foreign exchange had a less favorable impact on sales than forecasted, affecting financial performance.
Adjusted Gross Margin: The adjusted gross margin decreased compared to the prior year due to the impact of tariffs, which could affect profitability.
COVID Testing Sales Decline: A significant year-over-year decline in COVID test sales has impacted overall revenue growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future product contributions: Abbott expects increasing contributions from new products across its portfolio, emphasizing a balanced mix of iterative and transformative innovation.
Nutrition segment growth: Abbott plans to support future growth in its Nutrition segment by investing in its brands, such as Ensure and Glucerna, and launching new product versions tailored to consumer preferences.
Diagnostics growth outside China: Abbott anticipates durable underlying demand in markets outside China, with growth driven by innovative diagnostic tests like the Point of Care concussion test and high-sensitivity troponin test.
Biosimilar strategy in EPD: Abbott is advancing regulatory approvals for several biosimilars and remains on track with planned product and geographic launches.
Medical Devices growth: Abbott projects continued growth in Medical Devices, driven by double-digit growth in Diabetes Care, Electrophysiology, Cardiac Rhythm Management, Heart Failure, and Structural Heart segments.
Volt PFA catheter launch: Abbott plans to launch the Volt PFA catheter in the U.S. market next year, following positive feedback from its European launch.
Structural Heart business expansion: Abbott aims to expand its Structural Heart business with new regulatory approvals, such as TriClip in Japan and an expanded indication for the TAVR valve Navitor in Europe.
AVEIR leadless pacemaker: Abbott expects the AVEIR leadless pacemaker to continue driving growth in the Cardiac Rhythm Management segment, with market expansion and share gains in single and dual chamber pacing.
Esprit stent international launch: Abbott plans to offer the Esprit below-the-knee resorbable stent to international markets following its CE Mark approval.
Neuromodulation growth: Abbott anticipates growth in Neuromodulation, driven by the Eterna rechargeable spinal cord stimulation device's uptake in existing and new international markets.
Overall financial outlook: Abbott remains on track to deliver high single-digit organic sales growth and double-digit EPS growth for the year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are you comfortable with consensus sales and EPS for 2026?
A:Yes, Robert Ford expressed confidence in achieving consensus sales and EPS for 2026, citing three key growth drivers: underlying momentum in the current portfolio, new product launches, and easing of headwinds in diagnostics. He also highlighted investments in clinical trials and gross margin improvements.
Q:Can you provide more color on the U.S. and international diabetes market, particularly with the ketone sensor and CMS coverage of non-intensive type 2?
A:Robert Ford noted strong U.S. growth of 19% year-to-date, with some timing dynamics due to shelf restocking. He expects continued strong growth in the U.S. and internationally, driven by the new dual-analyte sensor and basal segment penetration. He also mentioned potential CMS coverage for type 2 non-insulin patients, though it is not included in the 2026 forecast.
Q:What is the feedback on Volt and its expected impact on EP growth?
A:Volt has received positive feedback in Europe, with advantages in focused energy delivery and integration with Ensite. It is expected to drive EP growth in 2026, with a U.S. launch anticipated around mid-2026. Abbott aims to leverage its full portfolio, including PFA and LAA tools, to sustain growth.
Q:What are the underlying drivers for the Diagnostics business and expectations for acceleration?
A:Robert Ford highlighted that the U.S. and international markets are driving growth, with Alinity system rollouts and new business captures. He expects mid-to-high single-digit growth in 2026 as headwinds from China VBP and DRG updates moderate.
Q:Can you explain the gross margin trajectory and factors affecting it?
A:Philip Boudreau explained that gross margin expansion is driven by operational improvements and tariff mitigation efforts. The Q3 sequential decline was due to plant maintenance shutdowns and the first impact of tariffs. Year-to-date gross margin expansion is 60 basis points, with a 57% outlook going forward.
Q:What are the drivers of double-digit ablation catheter growth and mapping franchise performance in EP?
A:Growth is driven by international markets and new product launches like the 13 French Agilis sheath and ICE. Abbott remains a leader in mapping cases and expects PFA penetration to reach 80% in the U.S. by 2026.
Q:What is Abbott's view on China’s growth outlook across Diagnostics, Medtech, and EPD?
A:China contributes less than 6% of Abbott's total revenue. Excluding Diagnostics, growth is around 5%-7%. Abbott remains committed to the market but emphasizes growth contributions from other geographies.
Q:What is the potential for the dual chamber leadless pacemaker market?
A:The low-voltage pacing market is estimated at $4 billion. Abbott aims to convert a significant portion with AVEIR, which has 50% penetration in single chamber and less than 10% in dual chamber, mostly in the U.S. International opportunities are also significant.
Q:What is Abbott’s strategy for left atrial appendage closure and Structural Heart growth?
A:Abbott is focusing on clinical trials and next-generation products like Amulet. The next-generation Amulet device is expected to launch in 2026 or 2027. Structural Heart remains a key growth area with a robust portfolio and investments in innovation.
Q:What are the barriers to CGM adoption in the basal segment in the U.S.?
A:Barriers include low awareness among primary care physicians and the need for more sampling programs and Epic integration. Abbott is investing in education and expanding its sales force to address these challenges.
Q:What is the status of NEC litigation and its impact on Nutrition?
A:Robert Ford stated that Abbott is committed to defending its products and labels. U.S. pediatric nutrition faced competitive impacts and WIC contract losses, but new contracts and product launches are expected to recover share in the coming quarters.
Q:What is the sustainability of double-digit growth in the device business?
A:Abbott has repositioned slower-growth segments like CRM and Vascular to mid-single-digit growth, complementing high-growth areas like Diabetes and Structural Heart. Investments in innovation and clinical trials support sustained growth.
Q:How is Abbott utilizing its balance sheet and cash?
A:Abbott is using cash for dividends, share buybacks, debt paydown, and internal investments. It remains open to strategic M&A opportunities that align with its portfolio and generate attractive returns.
Q:What are the growth prospects for mitral and tricuspid valve markets?
A:Growth depends on clinical evidence and data generation. Abbott is investing in trials for MitraClip and TriClip, with a focus on safety and efficacy. The mitral replacement valve shows strong potential to fulfill market expectations.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timing of CMS coverage for type 2 non-insulin patients and the exact launch date for the next-generation Amulet device. Additionally, they did not elaborate on the specific impact of tariffs on gross margins or the exact growth rate expectations for China in 2026.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AVEIR standard
Adult Nutrition
CE indication
CE technology
CEO Today
Cardiac Rhythm
Cardiology Congress
Care Diagnostics
Care Electrophysiology
Care concussion
Core Lab
Diabetes Care
Ensure
Glucerna
Heart Failure
Japan
Lab Diagnostics
Medical Devices
Point Care
Structural Heart
TriClip
acceleration digit
brand
consumer
detection heart
digit market
gram
health
market demand
product portfolio
protein
test sale
trend
uptake
vision
ABT Transcript
Abbott Laboratories (ABT) Q1 2026 Earnings Call Transcript
Positive4-16
The earnings call shows strong growth in key segments like Electrophysiology and Heart Failure, supported by product innovations and international expansion. Despite some challenges in CGM and Nutrition, the company has a diversified portfolio and strategic plans for growth. The Q&A reveals a cautious but optimistic outlook, with management addressing concerns and highlighting opportunities in underpenetrated markets. Overall, the positive growth drivers and strategic focus outweigh the conservative guidance, leading to a positive sentiment.
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Positive1-22
Abbott's earnings call reflects strong financial performance with double-digit EPS growth and improved margins. Despite slightly lower revenue growth guidance, the company anticipates recovery in the Nutrition segment and sustained growth across other divisions. Positive product developments, particularly in Medical Devices and Diagnostics, coupled with strategic initiatives, bolster a positive outlook. The Q&A session reveals confidence in overcoming short-term challenges and executing long-term growth strategies, contributing to an overall positive sentiment.
Abbott Laboratories (ABT) Q3 2025 Earnings Call Transcript
Positive10-15
The earnings call summary and Q&A indicate strong growth prospects in diabetes care and heart failure, with positive developments in new product launches like the dual-analyte sensor and AVEIR pacemaker. Despite headwinds in diagnostics and China's market, the company's strategic focus on innovation and expansion in high-growth segments like Structural Heart and EP suggest a positive outlook. However, the lack of detailed guidance on CMS coverage and tariff impacts introduces some uncertainty, but overall, the sentiment leans towards a positive stock price movement.
Abbott Laboratories (ABT) Q2 2025 Earnings Call Transcript
Positive7-17
Abbott's earnings call highlights strong financial performance, with high single-digit sales growth and double-digit EPS growth. The company is optimistic about future growth, driven by new product developments and market opportunities. Despite some headwinds, such as reduced COVID testing sales and challenges in China, Abbott is strategically positioned for continued success. The positive sentiment from analysts during the Q&A session reinforces this outlook, particularly in diabetes, CRM, and biosimilars. Overall, the sentiment leans positive, with potential for stock price appreciation in the near term.
ABT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
